THYROLAR-3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for THYROLAR-3 (THYROLAR-3).
THYROLAR-3 is a combination of synthetic T4 (levothyroxine) and T3 (liothyronine) that replaces or supplements endogenous thyroid hormones. T4 is converted to the active T3 in peripheral tissues. Thyroid hormones bind to thyroid hormone receptors (TRα and TRβ), regulating gene transcription involved in metabolism, growth, and development.
| Metabolism | Levothyroxine (T4) is metabolized via deiodination by deiodinases (D1, D2) to active T3 and reverse T3, as well as through conjugation (glucuronidation, sulfation) and hepatic microsomal pathways. Liothyronine (T3) is primarily metabolized by conjugation and deiodination. |
| Excretion | Renal (approximately 50% as unchanged drug and conjugates); fecal (~20%); biliary (~10%) |
| Half-life | Levothyroxine (T4): 6-7 days; Liothyronine (T3): 1-2 days. Clinical context: In hyperthyroidism, half-life shortened; in hypothyroidism, prolonged. |
| Protein binding | 99.7% bound to thyroxine-binding globulin (TBG), transthyretin, and albumin. |
| Volume of Distribution | 0.1-0.2 L/kg for T4; 0.4-0.6 L/kg for T3. Indicates extensive tissue distribution, especially for T3. |
| Bioavailability | Oral: T4 75-80%; T3 >90%. IV: 100%. |
| Onset of Action | Oral: T3 onset within 2-4 hours, peak effect 24-48 hours; T4 onset 3-5 days, peak 7-10 days. IV: T3 onset within minutes. |
| Duration of Action | T4: 3-4 weeks after discontinuation; T3: 2-4 days. Thyroid hormone replacement requires daily dosing due to T4's long half-life. |
| Molecular Weight | 650.97 |
Adults: Initial dose 30 mg orally once daily; adjust based on thyroid function tests. Typical maintenance dose 60-120 mg once daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment for renal impairment; monitor thyroid function more frequently due to potential altered drug clearance. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25-50% and titrate based on response. Child-Pugh C: Avoid use or initiate at 15 mg with careful monitoring. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at lower dose (15-30 mg once daily) due to increased sensitivity and higher prevalence of cardiac comorbidities; titrate slowly with close monitoring of cardiac function and thyroid parameters. |
| 1st trimester | Liothyronine contains T3 and T4; same as thyroid hormone. Not teratogenic at physiological doses. Requires dose adjustments during pregnancy to maintain euthyroid state. |
| 2nd trimester | Monitor thyroid function; dose may need increase. No known fetal harm. |
| 3rd trimester | Maintain euthyroid state; dose adjustments may be needed. No known adverse fetal effects. |
Clinical note
Comprehensive clinical and safety monograph for THYROLAR-3 (THYROLAR-3).
| Placental transfer | Transfers across placenta. T3 crosses to a lesser extent than T4, but both can affect fetal thyroid function. |
| Breastfeeding | Liothyronine (T3) is present in breast milk in low amounts. Dosage adjustments may be necessary to maintain maternal euthyroidism. Monitor infant for signs of hyperthyroidism (e.g., tachycardia). |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
Untreated thyrotoxicosisUncorrected adrenal cortical insufficiency
| Precautions | Cardiac toxicity at high doses, especially in elderly or patients with cardiovascular disease; risk of thyrotoxic crisis if overdosed; adrenal insufficiency in patients with concomitant adrenal disorders; altered anticoagulant effect; decreased bone mineral density with long-term TSH suppression. |
| Food/Dietary | Avoid soy products, high-fiber foods, and grapefruit juice as they may reduce absorption. Walnuts and cottonseed meal can also interfere. Take consistently relative to meals to minimize fluctuations. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Thyrolar-3 (liothyronine/levothyroxine) has no known teratogenic risk. Thyroid hormones do not cross the placenta in significant amounts. First trimester: fetal thyroid hormone production begins at 10-12 weeks. Untreated maternal hypothyroidism is associated with increased risk of miscarriage, preeclampsia, and neurocognitive deficits in offspring. Risk of fetal harm from therapeutic doses is minimal; inadequate treatment poses greater risk. |
| Fetal Monitoring | Monitor maternal thyroid function (TSH, free T4, free T3) every 4-6 weeks during pregnancy, with goal of maintaining euthyroidism. Dose adjustments may be needed, especially after delivery. Monitor fetal growth and development with serial ultrasound. Assess neonatal thyroid function at birth if maternal thyroid disease is present. |
| Fertility Effects | Hypothyroidism can impair ovulation and fertility. Euthyroidism achieved with Thyrolar-3 can restore normal menstrual cycles and improve fertility. No direct adverse effects on fertility from replacement therapy. |
| Clinical Pearls |
| THYROLAR-3 (liothyronine/levothyroxine combination) is used for thyroid hormone replacement. Monitor TSH levels closely; due to T3 component, TSH may be suppressed more than with T4 monotherapy. Avoid in patients with cardiovascular instability. Use with caution in elderly, starting at low doses. |
| Patient Advice | Take exactly as prescribed, usually once daily on an empty stomach. · Do not switch between brands without consulting your doctor. · Report symptoms of hyperthyroidism (palpitations, sweating, anxiety) or hypothyroidism (fatigue, weight gain, cold intolerance). · Consistent timing of dose is important; separate from supplements containing iron, calcium, or antacids by at least 4 hours. · Thyroid hormone affects many medications; inform all healthcare providers you are taking this. |